Determination of the Enantiomer of Apremilast and Its Intermediate by NP-HPLC

王慧君1,黄生军2,潘红娟1*

PDF(4616 KB)
主办:上海医药工业研究院
   中国药学会
   中国化学制药工业协会
ISSN 1001-8255   CN 31-1243/R   ZYGZEA
PDF(4616 KB)
Chinese Journal of Pharmaceuticals ›› 2016, Vol. 47 ›› Issue (10) : 1284. DOI: 10.16522/j.cnki.cjph.2016.10.017

Determination of the Enantiomer of Apremilast and Its Intermediate by NP-HPLC

Author information +
History +

Abstract

A NP-HPLC method was established for the chiral separation and determination of the enantiomer (2) of apremilast (1). A Daicel Chiralpak IF column was used, with the mobile phase of hexane∶ethanol∶isopropanol∶ diethylamine (30∶40∶30∶0.1) at the detection wavelength of 232 nm. It was linear for 2 in the range of 1.0—10 μg/ml. Its LOD was 0.084 μg/ml, and average recovery was 99.1%, with RSD of 1.59%. In addition, a NP-HPLC method was established for the chiral separation and determination of the intermediate of the enantiomer (4) in apremilast (3). A Daicel Chiralpak IF column was used, with the mobile phase of hexane∶isopropanol∶diethylamine (50∶50∶0.1) at the detection wavelength of 232 nm. It was linear for 4 in the range of 2.0—10 μg/ml. The LOD was 1.012 μg/ml. Its average recovery was 98.9%, with RSD of 3.20%.

Key words

apremilast / intermediate / enantiomer / HPLC / chiral separation / content determination

Cite this article

Download Citations
王慧君1,黄生军2,潘红娟1*. Determination of the Enantiomer of Apremilast and Its Intermediate by NP-HPLC. Chinese Journal of Pharmaceuticals. 2016, 47(10): 1284 https://doi.org/10.16522/j.cnki.cjph.2016.10.017

References

[1] 赵 倩, 孙 悦, 石 玉, 等. 磷酸二酯酶-4 抑制剂阿普司特[J]. 现代药物与临床, 2014, 29(4): 428—433.

[2] Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis [J]. Biochem Pharmacol, 2012, 83(12): 1583—1590.

[3] Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial [J]. Lancet, 2012, 380(9843): 738—746.

[4] 郭宗儒. 改造沙利度胺而成的新药阿普斯特[ J] . 药学学报, 2015, 50(7): 916—918

[5] Man HW, Schafer P, Wong LM, et al. Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2- methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-α inhibitor [J]. J Med Chem, 2009, 52(6): 1522—1524.

[6] 周立山, 戚聿新, 陈 军, 等. 一种合成阿普斯特中间体的制备方法: 中国, 104447445A [P]. 2015-03-25.

[7] Venkateswaralu J, Rajendiran C, Reddy NR, et al. Processes for the preparation of (S)-1-(3-ethoxy-4- methoxyphenyl)-2-methanesulfonylethylamine: US, 9187417 [P]. 2015-11-17.

[8] Connolly TJ, Ruchelman AL, Yong KHY, et al. Processes for the preparation of isoindole compounds and isotopologues thereof: US, 8981117 [P]. 2015-03-17.

[9] 蒙发明. HPLC 法测定阿普斯特对映异构体[J]. 化工中间体, 2015, (3): 37—38.
PDF(4616 KB)

418

Accesses

0

Citation

Detail

Sections
Recommended

/